Skip to content

Fluid Loading in Abdominal Surgery: Saline Versus Hydroxyethyl Starch (FLASH Study)

Fluid Loading in Abdominal Surgery: Saline Versus Hydroxyethyl Starch: A Double-blinded Multicenter Prospective Randomized Trial (FLASH Study)

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02502773
Acronym
FLASH
Enrollment
826
Registered
2015-07-20
Start date
2016-02-01
Completion date
2018-10-22
Last updated
2026-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Morbidity, Postoperative Mortality

Keywords

Goal-directed therapy, Fluid loading, Abdominal surgery, Postoperative morbidity, Postoperative mortality, Individualized goal-directed fluid therapy, Elective or emergency abdominal surgery, General Anesthesia, Moderate-to-high risk surgical patients

Brief summary

The primary purpose of the study is to evaluate whether the type of fluid (0.9% saline or 6% Hydroxyethyl starch 130/0.4) in the context of an individualized goal-directed fluid therapy is associated with a difference in morbidity and mortality within the first 14 days in patients at moderate-to-high risk of postoperative complications after abdominal surgery.

Detailed description

Fluid administration is the mainstay treatment for suspected hypovolemia during surgery, but the effects of different crystalloid and colloid solutions on outcome remain poorly explored in surgical patients. Two recent international multicenter studies (6S and CHEST studies) have shown that, compared to crystalloid solutions, the use of hydroxyethyl starch (HES) could be responsible for higher morbidity, especially renal failure, and mortality in ICU patients, thus leading to a recent restriction of their range of indications. In contrast, in surgical patients, recent meta-analyses have concluded on the absence of difference in terms of mortality and postoperative renal failure between crystalloids and latest generation HES. Excessive fluid administration during surgery is associated with increased risk of postoperative morbidity, including renal dysfunction and mortality. It has been suggested that, compared with the volume-restoring effects of colloids, crystalloid use may require the administration of higher fluid volumes, which may contribute to poorer outcomes. In the surgical context, clinical trials and meta-analyses have shown that individualized goal-direct fluid administration can reduce postoperative morbidity. Although most GDT studies have used colloid solutions for fluid loading, the effects of the type of fluids are currently unknown and crystalloids are proposed for first-line therapy. The proposed Flash multicenter study will be conducted to assess if the use of HES or crystalloid solutions during an individualized GDT contribute to outcome differences in patients at moderate-to-high risk of postoperative complications after abdominal surgery. As these fluids are widely used during surgery and because of current concerns about the risks related to the use of HES-based products in ICU patients, the trial will provide important data to clinicians involved in perioperative care.

Interventions

DRUGHydroxethyl starch

Sponsors

University Hospital, Clermont-Ferrand
Lead SponsorOTHER
Agence Nationale de sécurité du Médicament
CollaboratorOTHER
Programme Hospitalier de Recherche Clinique (AOI N° 2013 _ Futier)
CollaboratorUNKNOWN
Société Française Anesthesie-Réanimation (SFAR)
CollaboratorUNKNOWN

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

All adult patients who * Undergo elective or emergency abdominal surgery under general anesthesia * With an estimated surgical duration greater than or equal to 2 hours * With moderate-to-high risk of postoperative complications defined by an AKI risk index≥ class 3, as defined by the presence of at least 4 of the following factors: age\> 56 years, male gender, intraperitoneal surgery, active congestive heart failure, ascites, hypertension, emergency surgery, mild or moderate renal insufficiency, diabetes mellitus treated by oral or insulin therapy

Exclusion criteria

The following patients will not be evaluated for inclusion: * Age \<18 years * Preoperative acute heart failure * Preoperative acute coronary insufficiency * Preoperative severe renal failure (defined by creatinine clearance \<30 ml/min or requiring renal replacement therapy) * Preoperative shock defined by the need for vasoactive amines * History of allergy with the use of 6% Hydroxethyl starch 130/0.4 * Contraindication to the use of HES: sepsis, burnt patient, renal insufficiency or dialysis, cerebral hemorrhage, ICU patient , hypervolemia, lung edema, dehydration, severe hypernatremia or severe hyperchloremia, severe hepatic insufficiency, congestive heart failure, severe coagulopathy, organ transplant * Patient's or relative's refusal to participate * Parturient or breastfeeding woman * Protected major (guardianship)

Design outcomes

Primary

MeasureTime frameDescription
Renal dysfunctionduring the first 14 postoperative daysRenal dysfunction (defined by KDIGO stage 1 or higher)
Pulmonary complicationduring the first 14 postoperative daysPulmonary complication (defined by the need for noninvasive or invasive ventilatory assistance for postoperative acute respiratory failure)
Cardiovascular complicationduring the first 14 postoperative daysCardiovascular complication (defined by the development of acute heart failure)
Infectious complicationduring the first 14 postoperative daysInfectious complication (defined by the development of sepsis, severe sepsis or septic shock)
Surgical complicationduring the first 14 postoperative daysSurgical complication (defined as the need for surgical reoperation)

Secondary

MeasureTime frameDescription
Total fluid volumeduring the surgical period and the first 24 postoperative hoursTotal fluid volume (0.9% saline and HES 130/0.4)
Volume of blood lossduring the surgical period and the first 24 postoperative hours
Renal complications : oliguriawithin 14 daysPostoperative complications
Cardiovascular complicationswithin 14 daysPostoperative complications
Respiratory complicationswithin 14 daysPostoperative complications
SIRS scorewithin 14 daysPostoperative complications
Infectious complicationswithin 14 daysPostoperative complications
Surgical complicationswithin 14 daysPostoperative complications
Severity organ failure assessment score from postoperativeDay-1 to Day-7
Unexpected ICU admission (or readmission) following surgerywithin 28 days
All-cause mortality28 days
Serum lactatefrom Day-1 to Day-7
C-reactive proteinfrom Day-1 to Day-7
Plasma chloridefrom Day-1 to Day-7
number of units of packed red blood cellsduring the surgical period and the first 24 postoperative hours

Countries

France

Contacts

PRINCIPAL_INVESTIGATOREmmanuel FUTIER

University Hospital, Clermont-Ferrand

PRINCIPAL_INVESTIGATORJean-Etienne BAZIN

University Hospital, Clermont-Ferrand

PRINCIPAL_INVESTIGATORSamir JABER

University Hospital, Montpellier

PRINCIPAL_INVESTIGATORJulien POTTECHER

CHRU Strasbourg

PRINCIPAL_INVESTIGATORAlexandre OUATTARA

University Hospital, Bordeaux

PRINCIPAL_INVESTIGATORThomas LESCOT

Hôpital Saint-Antoine (APHP)

PRINCIPAL_INVESTIGATORHélène BELOEIL

Rennes University Hospital

PRINCIPAL_INVESTIGATORGilles LEBUFFE

CHRU LILLE

PRINCIPAL_INVESTIGATORPhilippe CUVILLON

CHU Nîmes

PRINCIPAL_INVESTIGATORJulien BUREY

Hôpital Tenon (APHP)

PRINCIPAL_INVESTIGATORWilly-Serge MFAM

CH ORLEANS

PRINCIPAL_INVESTIGATORVincent PIRIOU

Hospices Civils de Lyon

PRINCIPAL_INVESTIGATORMarc LEONE

AP-HM

PRINCIPAL_INVESTIGATORSébastien BERTRAN

CHU Nîmes

PRINCIPAL_INVESTIGATORMarion FAUCHER

Institut Paoli-Calmettes

PRINCIPAL_INVESTIGATORCatherine PAUGAM-BURTZ

Hôpital Beaujon

PRINCIPAL_INVESTIGATORLionel VELLY

AP-HM

PRINCIPAL_INVESTIGATOROlivier HUET

CHU Brest

PRINCIPAL_INVESTIGATORSigismond LASOCKI

University Hospital, Angers

PRINCIPAL_INVESTIGATORPierre SAINT-LEGER

CH VALENCIENNES

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 6, 2026